---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-100456"
form_type: "8-K/A"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2025-10-17T23:59:59+00:00"
generated_at: "2026-05-17T03:25:31.986090+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics creates CVRs entitling holders to 50% of net proceeds from TTX-MC138 asset sales

## Summary
- Each share of common stock held as of Oct 20, 2025 receives one CVR; CVRs pay 50% of Net Proceeds from future Upfront or Milestone payments on TTX-MC138 program disposals.
- CVR term is 7 years from Oct 8, 2025; distributions paid quarterly within 60 days after each quarter end, starting with Q4 2025 if proceeds are received.
- CVRs are non-transferable except by Permitted Transfers (inheritance, court order, merger); no certificates, book-entry only via DTC.
- Vstock Transfer, LLC appointed as Rights Agent; Company must deliver payment statement and funds to Rights Agent within 60 days of each quarter.
- Net Proceeds = Gross Proceeds minus Permitted Deductions (taxes, out-of-pocket costs, business development expenses, etc.).

## SEC filing metadata
- accession: 0001104659-25-100456
- form_type: 8-K/A
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2025-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465925100456/0001104659-25-100456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465925100456/tm2528999d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-100456
- JSON: https://secwatch.observer/filing/0001104659-25-100456.json
- Plain text: https://secwatch.observer/filing/0001104659-25-100456.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.